Sonnet BioTherapeutics, listed in the US, to acquire Hyperliquid through a merger

Son Min

Summary

Sonnet BioTherapeutics announced plans to launch Hyperliquid Strategies Inc. through a merger.
The newly established company will focus on Hyperliquid (HYPE) accumulation as its main financial strategy.
The company expects to hold Hyperliquid and $305,000,000 in cash.

Sonnet BioTherapeutics, a biotechnology company listed on Nasdaq, is set to launch Hyperliquid Strategies Inc., a company for accumulating Hyperliquid (HYPE), through a merger.

According to The Block on the 14th (local time), Sonnet BioTherapeutics announced that it will establish Hyperliquid Strategies Inc. through a merger with the special purpose vehicle (SPV) Rorschach I LLC. The existing company will be incorporated as a subsidiary of the new company.

Hyperliquid Strategies Inc. will make Hyperliquid accumulation its main financial strategy. It is expected to hold 12,600,000 HYPE and $305,000,000 in cash.

HYPE